Our Recommendations
New Publications
- Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- Manual del Vacunador Vacuna MODERNA para uso pediátrico de 6 a 11 años Campaña Nacional de Vacunación contra la COVID-19 (2022)
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
Filter
132
Featured
Recommendations
24
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
COVID-19
52
Guidelines
11
Information, Education and Communication (IEC)
7
Studies & Reports
4
x MEDBOX Issue Brief & Annual Reports x
2
Women & Child Health
2
Countries
1
Policies
1
Immunization
1
Toolboxes
Vaxzevria (Astra Zeneca)
26
Research & Pipeline
26
Biontech/Pfizer Comirnaty
23
Inactivated COVID-19 Vaccines
18
mRna Vaccines general
14
Vector-based Vacines General
14
Moderna
13
Johnson & Johnson
8
Covaxin
6
Sputnik V
3
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
orientations provisoires, première publication le 25 janvier 2021, mise à jour le 15 juin 2021, mise à jour le 19 novembre 2021
21 Dec 2021. Slideset updated regularly to include the latest data and guidance on COVID-19 vaccines, including implications of emerging SARS-CoV-2 variants
This website has been created to provide accurate and up-to-date information about Sputnik V.
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h...
Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do...
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments and vaccines to enable promising medicines to reach patients as soon as possible. It is also interacting with medicine developers and making use of real-world data to monitor the safety and effectiveness of medicines use...
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
